Stock listing

Lang & Schwarz:A41SET Moleculin Biotech, Inc. Aktie

German listing (Lang & Schwarz) of Moleculin Biotech, Inc. · home listing NASDAQ:MBRX

Follow Moleculin Biotech, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:MBRX

$0.28 USD -0.09 (-24.2%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:MBRX

Moleculin Biotech, Inc. logo
Ticker
Lang & Schwarz:A41SET
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Calls

Replays

  • Moleculin Biotech (NASDAQ:MBRX) Q1 2025 Earnings Call

    Wed, May 14, 2025 · 8:30 AM ET

    Watch Transcript

  • Moleculin Biotech (NASDAQ:MBRX) Q4 2024 Earnings Call

    Mon, Mar 24, 2025 · 8:30 AM ET

    Watch Transcript

  • Moleculin Biotech (NASDAQ:MBRX) Q3 2024 Earnings Call

    Mon, Nov 11, 2024 · 8:30 AM ET

    Watch Transcript

Latest news

Moleculin Announces Reverse Stock Split

Oct 16, 2026

Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit

Oct 7, 2026

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

Sep 29, 2026

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

Sep 28, 2026

Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

Sep 25, 2026

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

Sep 23, 2026

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

Sep 11, 2026

Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

Aug 27, 2026

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Aug 14, 2026

Moleculin Announces Pricing of $9.3 Million Public Offering

Jul 31, 2026

All Moleculin Biotech, Inc. news

Financings

  • Not stated

    Aug 14, 2026

    Closed: US$9.3M raised

    Use of proceeds: To support planned operations into the first quarter of 2027

    Closed Aug 14, 2026

Read by 6ix AI from the company's releases

Decks

Moleculin Biotech, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
45 in the last 12 months · 243 in all · newest Oct 16, 2026 · oldest 2019
Calls
10 calls with a replay · 10 with a transcript · latest May 14, 2025
Decks
53 decks · latest Oct 16, 2026

Where Moleculin Biotech, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MBRX · Home listingNASDAQUnited StatesUSD
BOATS:MBRXBOATSUnited StatesUSD
LSE:0K2HLSEUnited KingdomUSD
gettex:MOL0gettexGermanyEUR
Frankfurt:MOL0FrankfurtGermanyEUR
Munich:MOL0MunichGermanyEUR
Lang & Schwarz:A41SET · This pageLang & SchwarzGermanyEUR

Log in to ask 6ix AI your own questions about Moleculin Biotech, Inc.